Skip to content
Parakho

Dipna Pharmachem Ltd

BSE 543594

Q4 FY26

Revenue
₹2.02 Cr
Profit after tax
₹0.18 Cr

As filed with the exchange, standalone basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with BSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, standalone basis
₹ croreQ4 FY26vs a year agoFY26
Revenue from operations2.02—129.08
Other income0.03—0.03
Total income2.05—129.11
Employee benefit expense0.10—0.41
Finance costs0.23—1.46
Depreciation & amortisation0.00—0.01
Total expenses1.83—125.56
Profit before tax0.22—3.54
Tax expense0.04—0.91
Profit after tax0.18—2.63
Total comprehensive income0.18—2.63
Earnings per share
Earnings per share, basic₹0.07₹1.00
Earnings per share, diluted₹0.07₹1.00

Q4 FY26 and FY26 — from the company’s filing with BSE. Source

Q4 FY26 results for every company Parakho holds

Why the dash

Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.

Earnings call

Dipna Pharmachem Ltd has not filed a concall transcript in the last 4 quarters.

Filings

12 shown · 24 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Industry

Healthcare › Pharmaceuticals

Classification as published by BSE.

Companies also in Pharmaceuticals, in alphabetical order

All 196 companies in Pharmaceuticals

Page generated from filings held to 30 Sept 2026.